UB VV200
Alternative Names: UB VV200 + TumorTag cocktail - Umoja Biopharma; UB VV200 with TumorTag cocktail - Umoja Biopharma; UBVV200Latest Information Update: 28 Jun 2025
At a glance
- Originator Umoja Biopharma
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Osteosarcoma
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in Osteosarcoma(In adolescents, In children, Recurrent, Second-line therapy or greater, In adults) in USA (Parenteral)
- 17 May 2023 Pharmacodynamics data from preclinical trial in solid tumours released by Umoja Biopharma
- 06 Apr 2023 Umoja plans to file IND application for UB VV200 along with additional Tags for Solid tumour in 2024 (Umoja pipeline, April 2023)